| |
|
|
|
IBC LifeSciences, Hynes Convention Center Boston, MA
10/21/2014-10/23/2014
BioProcess International is the one event that brings a proven track record of delivering a highly targeted group of bioprocess professionals, to create a one-of-a-kind, face-to-face interactive experience – all under one roof. Register for an exhibit hall & keynote pass for your chance to experience innovation and networking at its best first-hand, including: • 1500+ Attendees • 150+ Exhibitors • 80+ Scientist Posters • 5 Keynote Presentations • 25+ New Product Launches • Technology Workshops • The BioProcess International Theater NEW • Casual Themed Networking Receptions • Networking Lounges • BPI Passport Prize Program
|
|
|
|
|
|
|
|
Organized by:
|
|
IBC LifeSciences Westborough |
|
|
Invited Speakers:
|
|
- John G. Cox Executive Vice President of Pharmaceutical Operations & Technology, Biogen Idec
- Ralph Lambalot, Ph.D. Vice President, Biologics Development, AbbVie
- Robert Mattaliano, Ph.D. Vice President and Deputy Head of Global Biotherapeutics Development, Sanofi R&D
- Geoffrey Ling, M.D., Ph.D. Director, Biological Technologies Office, DARPA
- Ganesh V. Kaundinya, Ph.D. Co-Founder and Chief Scientific Officer, Momenta Pharmaceuticals
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
N/A
|
|
|
|
|
|
|
|
Registration:
|
|
One-Day Exhibit Hall & Keynote Passes are available for qualified professionals with priority code 143. For complete pass information and qualification criteria visit: http://bit.ly/1qLrXIQ. Full conference passes to access over 160 presentations and the BPI partnering360 networking tool are also available at: www.IBCLifeSciences.com/BPI *Qualified Professionals: Exhibit Hall & Keynote pass purchases are only made available for qualified researchers, scientists, engineers, quality professionals and executives from biotechnology, biopharmaceutical or pharmaceutical organizations. All registrations will be reviewed and IBC reserves the right to provide this access only to those who do meet the qualified criteria.
|
|
|
|
|
|
|
|
|